Literature DB >> 7074586

Carcinoembryonic antigen serum levels in patients with squamous cell carcinoma of the uterine cervix: clinical significance.

E R te Velde, J P Persijn, R E Ballieux, J Faber.   

Abstract

In 114 patients with invasive cervical cancer of the squamous cell type pretreatment CEA levels were determined. An individual upper limit of the normal range was derived taking into account the smoking habits and the age of each patient. Pretreatment CEA levels exceeding the upper limit of normal concurred with a very poor prognosis, regardless of the stage of the tumor. Moreover, in 92 patients longitudinal CEA patterns were established. The median follow-up time of the nonrecurrence patients was four years. Three patients appeared to be exclusively associated with the presence of recurrent cancer. The median lead-time obtained in patients demonstrating such patterns, was 13 weeks. The clinical value and the possible therapeutic consequences of the findings presented are discussed in relation to the available knowledge of tumor growth in cervical cancer.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7074586     DOI: 10.1002/1097-0142(19820501)49:9<1866::aid-cncr2820490920>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review).

Authors:  Miho Iida; Kouji Banno; Megumi Yanokura; Kanako Nakamura; Masataka Adachi; Yuya Nogami; Kiyoko Umene; Kenta Masuda; Iori Kisu; Takashi Iwata; Kyoko Tanaka; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-06-23

2.  Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.

Authors:  Maria R Parkhurst; Jayne Joo; John P Riley; Zhiya Yu; Yong Li; Paul F Robbins; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.